BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15507522)

  • 41. Role of human telomerase reverse transcriptase and telomeric-repeat binding factor proteins 1 and 2 in human hematopoietic cells.
    Yamada K; Yajima T; Yagihashi A; Kobayashi D; Koyanagi Y; Asanuma K; Yamada M; Moriai R; Kameshima H; Watanabe N
    Jpn J Cancer Res; 2000 Dec; 91(12):1278-84. PubMed ID: 11123427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
    Rha SY; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer MP; Roodman GD; Hurley L; Von Hoff D
    Clin Cancer Res; 2000 Mar; 6(3):987-93. PubMed ID: 10741725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.
    Berardinelli F; Coluzzi E; Sgura A; Antoccia A
    Mutat Res Rev Mutat Res; 2017 Jul; 773():204-219. PubMed ID: 28927529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Telomeres and telomerase in human leukemias.
    Shay JW; Werbin H; Wright WE
    Leukemia; 1996 Aug; 10(8):1255-61. PubMed ID: 8709628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
    Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
    Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of telomerase recruitment and cancer cell death.
    Nakashima M; Nandakumar J; Sullivan KD; Espinosa JM; Cech TR
    J Biol Chem; 2013 Nov; 288(46):33171-80. PubMed ID: 24097987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Telomeres and telomerase in hematologic neoplasia.
    Ohyashiki JH; Sashida G; Tauchi T; Ohyashiki K
    Oncogene; 2002 Jan; 21(4):680-7. PubMed ID: 11850796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant.
    Delhommeau F; Thierry A; Feneux D; Lauret E; Leclercq E; Courtier MH; Sainteny F; Vainchenker W; Bennaceur-Griscelli A
    Oncogene; 2002 Nov; 21(54):8262-71. PubMed ID: 12447689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
    Batova A; Shao LE; Diccianni MB; Yu AL; Tanaka T; Rephaeli A; Nudelman A; Yu J
    Blood; 2002 Nov; 100(9):3319-24. PubMed ID: 12384433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Telomeres and telomerase in leukemias].
    Werda L; Skotnicki AB
    Przegl Lek; 1999; 56(10):668-70. PubMed ID: 10695383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line.
    Pantic M; Zimmermann S; Waller CF; Martens UM
    Int J Oncol; 2005 May; 26(5):1227-32. PubMed ID: 15809713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.
    Bechter OE; Eisterer W; Pall G; Hilbe W; Kühr T; Thaler J
    Cancer Res; 1998 Nov; 58(21):4918-22. PubMed ID: 9810000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MST-312 Alters Telomere Dynamics, Gene Expression Profiles and Growth in Human Breast Cancer Cells.
    Gurung RL; Lim SN; Low GK; Hande MP
    J Nutrigenet Nutrigenomics; 2014; 7(4-6):283-98. PubMed ID: 26022559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platinum(II) phenanthroimidazole G-quadruplex ligand induces selective telomere shortening in A549 cancer cells.
    Mancini J; Rousseau P; Castor KJ; Sleiman HF; Autexier C
    Biochimie; 2016 Feb; 121():287-97. PubMed ID: 26724375
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Telomeres, senescence, and hematopoietic stem cells.
    Zimmermann S; Martens UM
    Cell Tissue Res; 2008 Jan; 331(1):79-90. PubMed ID: 17960423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of telomeres in Etoposide induced tumor cell death.
    Jeyapalan J; Leake A; Ahmed S; Saretzki G; Tilby M; von Zglinicki T
    Cell Cycle; 2004 Sep; 3(9):1169-76. PubMed ID: 15326395
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells.
    Phatak P; Dai F; Butler M; Nandakumar MP; Gutierrez PL; Edelman MJ; Hendriks H; Burger AM
    Clin Cancer Res; 2008 Jul; 14(14):4593-602. PubMed ID: 18628474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.
    Damle RN; Batliwalla FM; Ghiotto F; Valetto A; Albesiano E; Sison C; Allen SL; Kolitz J; Vinciguerra VP; Kudalkar P; Wasil T; Rai KR; Ferrarini M; Gregersen PK; Chiorazzi N
    Blood; 2004 Jan; 103(2):375-82. PubMed ID: 14504108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.